Interpace Biosciences, Inc.
IDXGD
$6.98
-$0.02-0.29%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 1.10% | -2.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.10% | -2.08% | |||
| Cost of Revenue | 11.19% | -1.64% | |||
| Gross Profit | -4.25% | -2.32% | |||
| SG&A Expenses | 11.99% | 27.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.39% | 13.85% | |||
| Operating Income | -71.42% | -50.68% | |||
| Income Before Tax | -70.87% | -26.19% | |||
| Income Tax Expenses | -78.81% | 101.42% | |||
| Earnings from Continuing Operations | -67.99% | -96.35% | |||
| Earnings from Discontinued Operations | 1.82% | -15.79% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -78.09% | -96.82% | |||
| EBIT | -71.42% | -50.68% | |||
| EBITDA | -63.90% | -48.18% | |||
| EPS Basic | -81.96% | -99.38% | |||
| Normalized Basic EPS | -76.21% | -90.14% | |||
| EPS Diluted | -78.08% | -96.81% | |||
| Normalized Diluted EPS | -71.09% | -49.21% | |||
| Average Basic Shares Outstanding | 21.57% | 414.47% | |||
| Average Diluted Shares Outstanding | 0.02% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||